SARS-CoV-2

• Surrogate virus neutralisation test (sVNT) for semi-quantitative detection of neutralising antibodies inhibiting the binding of SARS-CoV-2 S1/RBD to ACE2 receptors of the host cells
• Supports the evaluation of the immune response after SARS-CoV-2 infection or vaccination using S1/RBD-based vaccines
• Very high agreement of results compared with a plaque reduction neutralisation test (PRNT50)
• Established ELISA method – suitable for routine laboratory diagnostics, no BSL-3 laboratory required
• Automatable even for high-throughput analysis, results available in approx. 2 hours
• Modelled upon nature: Neutralising antibodies in the sample compete with the host-cell receptor (ACE2) for the binding to S1/RBD in the first incubation step, no preadsorption required
• Multispecies test- application with animal specimen possible for research use only

1. EUROIMMUN Automation Solutions:

EUROLabWorkstation ELISA, Analyzer I, Analyzer I-2P and Sprinter XL

• Automation of the Anti-SARS-CoV-2 ELISAQuick and reliable ELISA processing
• Automation of the Anti-SARS-CoV-2 NCP ELISAQuick and reliable ELISA processing

For further information on our automation options, please contact our experts of product management for instruments and software.

2. Processing on all common open ELISA platforms

• Specific detection of IgG antibodies against SARS-CoV-2 using the S1 domain of the spike protein including the immunologically relevant receptor binding domain (RBD)
• RBD represents important target antigen for virus neutralising antibodies
• Worldwide programs for vaccine development use the spike protein as antigen
• Available as ELISA for semi-quantitative and quantitative determination (same cut-off calibrator); quantitative results can NOW be given in standardised units!
• Excellent performance and good correlation with different test systems for the detection of neutralising antibodies confirmed in external studies
• Validated for serum, plasma and dried capillary blood as sample material, complete automation possible

Customer comments and testimonials about SARS-CoV-2 ELISA (IgG)

^{*Optimized for processing with the EUROLabWorkstation ELISA}

Products may not be licensed in accordance with the laws and regulations in all countries.

Information -
SARS-CoV-2 variants

According to substantiated evaluation by our scientists, no influence of the known mutations in the SARS-CoV-2 genome (this also applies to the new SARS-CoV-2 variants VOC*202012/01, 501.V2 and 501Y.V3) on the performance of the test systems is to be expected. Find out more here.

Please contact your
local distributor for further information.